Skip to content

Risk Stratification Study of Prognosis in Non-Diabetic Heart Failure Patients Treated with SGLT2 Inhibitors

Risk Stratification Study of Prognosis in Non-Diabetic Heart Failure Patients Treated with SGLT2 Inhibitors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125573
Enrollment
Unknown
Registered
2026-05-28
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure (HF)

Interventions

No Adverse Event Group:None
Adverse Event Group:None

Sponsors

The Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Adult patients aged 18 years or older; 2. Diagnosed with heart failure (HF), including HFrEF, HFmrEF, or HFpEF, based on clinical manifestations and echocardiographic parameters clearly defined in the guidelines; 3. No history of diabetes, with no diabetes diagnosis found in admission or past records, or fasting blood glucose and HbA1c levels not reaching the diagnostic criteria for diabetes; 4. Have received SGLT2 inhibitor treatment for 1 month or more, with complete treatment and follow-up records; 5. Follow-up data are complete, with obtainable information on the timing of prognostic events and outcome data.

Exclusion criteria

Exclusion criteria: 1. Patients with clear diabetes or prediabetes progressing to diabetes. 2. Patients with severe liver or kidney dysfunction (e.g., glomerular filtration rate eGFR < 30 mL/min/1.73 m^2); 3. Patients with severe acute diseases (e.g., acute myocardial infarction, acute pulmonary embolism, acute infection, shock, etc.) that may significantly interfere with prognosis assessment; 4. Patients who have changed key heart failure treatment plans (e.g., ß-blockers, ARNI, etc.) within the past 3 months, resulting in difficulty distinguishing drug effects; 5. Patients lacking key baseline data, such as echocardiography parameters, hematological indicators, follow-up event records, etc.; 6. Patients who withdraw, are lost to follow-up, or have incomplete data during follow-up, making prognosis assessment impossible.

Design outcomes

Primary

MeasureTime frame
Laboratory indicators, such as N-terminal pro B-type natriuretic peptide, serum creatinine, serum potassium, and serum albumin levels;Echocardiography parameters, such as left ventricular eject;

Countries

China

Contacts

Public ContactMa Yanfeng

The Affiliated Hospital of Xuzhou Medical University

mayanfeng8998@163.com+86 516 8580 2369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026